DOCSLIB.ORG

Figure S1. Rhod 2 Staining of Intracellular Calcium Depletion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Figure S1. Rhod 2 Staining of Intracellular Calcium Depletion Figure S1. Rhod 2 staining of intracellular calcium depletion. Confocal microscopy bright field and fluorescent images x20 magnification of one UMM (OMM2.3) and one CMM (A375) line after staining with 1 µM Rhod 2 and 48 h of treatment with 0, 1, 3 and 8 µM amlodipine. UMM, uveal malignant melanoma; CMM, cutaneous malignant melanoma. Figure S2. Spheroid colonies. Light microscopy x5 magnification images of 3D spheroid colonies in CMM and UMM lines. Images were acquired just prior to the addition of 20 µM amlodipine in the treated groups or an equivalent volume of DMSO in control groups (Day 0). The same colonies were then visualized again after 48 h of treatment (Day 2). UMM, uveal malignant melanoma; CMM, cutaneous malignant melanoma. Figure S3. Senescence assay for amlodipine-induced cell death. Light microscopy x20 magnification images of CMM (A375, CHL-1 and IPC298) and UMM (MP41) lines when treated with amlodipine at 3 dose points over a 48-h period. Senescence is indicated with blue dye. UMM, uveal malignant melanoma; CMM, cutaneous malignant melanoma. Table SI. High-throughput drug screening compounds: Ranked list of the 1,018 screened compounds based on observed proliferation ratio. Rank Proliferation Compound ratio 1 0.00000 Fluoxetine HCl 2 0.00042 Amlodipine (Norvasc) 3 0.00042 Dronedarone HCl (Multaq) 4 0.00049 Prochlorperazine dimaleate 5 0.00055 Afatinib (BIBW2992) 7 0.00055 AMG-073 HCl (cinacalcet hydrochloride) 8 0.00055 Amlodipine besylate (Norvasc) 6 0.00055 Crizotinib (PF-02341066) 9 0.00064 Crystal violet 10 0.00074 Alexidine HCl 11 0.00074 Benzethonium chloride 14 0.00074 Cetrimonium bromide 13 0.00074 Domiphen bromide 15 0.00074 Thioridazine HCl 12 0.00074 Trifluoperazine 2HCl 16 0.00083 Bosutinib (SKI-606) 17 0.00085 Mitoxantrone hydrochloride 18 0.00085 Duloxetine HCl (Cymbalta) 19 0.00099 Cetylpyridinium chloride 20 0.00099 Thonzonium bromide 21 0.00106 Paroxetine HCl 22 0.00106 Carfilzomib (PR-171) 23 0.00110 Nebivolol (Bystolic) 24 0.00124 Nelfinavir mesylate 25 0.00124 Triflupromazine HCl 26 0.00127 Daunorubicin HCl (Daunomycin HCl) 27 0.00138 Doxorubicin (Adriamycin) 28 0.00149 Sertraline HCl 29 0.00169 Bazedoxifene HCl 30 0.00170 Loperamide hydrochloride 31 0.00173 Penfluridol 32 0.00193 Bortezomib (Velcade) 33 0.00197 9-Aminoacridine 34 0.00220 Epirubicin hydrochloride 35 0.00233 Aliskiren hemifumarate 37 0.00234 Chlorpromazine (Sonazine) 38 0.00234 Maprotiline hydrochloride 36 0.00234 Menadione 39 0.00247 Ouabain 40 0.00247 Sunitinib malate (Sutent) 41 0.00271 Cepharanthine 42 0.00271 Terfenadine 43 0.00321 Emetine 44 0.00519 Nitarsone 45 0.00568 Digoxigenin 46 0.00692 Clemastine fumarate 47 0.00741 Disulfiram (Antabuse) 48 0.01042 Clomipramine hydrochloride (Anafranil) 49 0.01048 Adefovir Dipivoxil (Preveon, Hepsera) 50 0.01212 Vinorelbine tartrate 51 0.01356 Proadifen HCl 52 0.01381 Clomifene citrate (Serophene) 53 0.01603 Thiostrepton 54 0.01762 Ethacridine lactate monohydrate 55 0.02190 Toremifene citrate (Fareston, Acapodene) 56 0.02229 Vorinostat (SAHA) 57 0.02435 Topotecan HCl 58 0.02618 Lomerizine HCl 59 0.02850 Ivacaftor (VX-770) 60 0.03878 Camptothecin 61 0.04406 Ziprasidone hydrochloride 62 0.04793 Sorafenib (Nexavar) 63 0.05525 Pyrithione zinc 64 0.05687 Ticagrelor 65 0.05819 Masitinib (AB1010) 66 0.09668 Meclocycline sulfosalicylate 67 0.11141 Asenapine 68 0.12470 Indacaterol maleate 69 0.13885 Carvedilol 70 0.13952 Primaquine diphosphate 71 0.13963 Bleomycin sulfate 72 0.15462 Imatinib Mesylate 73 0.15497 Solifenacin succinate 74 0.15876 Amitriptyline HCl 75 0.15924 R-(-)-Apomorphine HCl hemihydrate 76 0.18245 Pitavastatin calcium (Livalo) 77 0.20079 Ivermectin 78 0.20520 Desloratadine 79 0.20598 Pentamidine 80 0.20982 Aprepitant (MK-0869) 81 0.22060 Dapoxetine hydrochloride (Priligy) 82 0.22252 Cilnidipine 83 0.23689 Nifuroxazide 84 0.23974 Lonidamine 85 0.24045 Gemcitabine (Gemzar) 86 0.24876 Elvitegravir (GS-9137) 87 0.25162 Doxycycline HCl 88 0.25189 Cephalomannine 89 0.25404 Fenoprofen calcium 90 0.26206 Teniposide (Vumon) 91 0.26917 Chlorpheniramine maleate 92 0.27078 Tenofovir disoproxil Fumarate 93 0.29291 Riluzole (Rilutek) 94 0.29338 Mycophenolic (Mycophenolate) 95 0.29350 Evista (Raloxifene hydrochloride) 96 0.29821 XL-184 (Cabozantinib) 97 0.30870 Vinblastine 98 0.31176 Nisoldipine (Sular) 99 0.31183 Simvastatin (Zocor) 100 0.31240 Azacitidine (Vidaza) 101 0.32977 Pizotifen malate 102 0.33260 Albendazole oxide (Ricobendazole) 103 0.33269 Procodazole 104 0.33805 Azaguanine-8 105 0.34341 Lamivudine (Epivir) 106 0.34524 Ciclopirox (Penlac) 107 0.34591 Fluvoxamine maleate 108 0.35166 Clofarabine 109 0.35722 Valnemulin HCl 110 0.35954 Azelastine hydrochloride (Astelin) 111 0.36185 Licofelone 112 0.36509 Rotigotine 113 0.36512 Cladribine 114 0.36527 Darifenacin HBr 115 0.36631 Celecoxib 116 0.36805 Diperodon HCl 117 0.37690 L-Adrenaline (Epinephrine) 118 0.37842 Ciclopirox ethanolamine 119 0.38325 Nitazoxanide (Alinia, Annita) 120 0.38568 Acemetacin (Emflex) 121 0.39396 Trimipramine maleate 122 0.39694 Vincristine 123 0.40995 Coumarin 124 0.41325 Dasatinib (BMS-354825) 125 0.41573 Etravirine (TMC125) 126 0.41657 Doxazosin mesylate 127 0.42478 Cabazitaxel (Jevtana) 128 0.42821 Albendazole (Albenza) 129 0.43579 Chlorprothixene 130 0.43960 Lapatinib Ditosylate (Tykerb) 131 0.44312 Etoposide (VP-16) 132 0.44600 OSI-420 (Desmethyl erlotinib) 133 0.45329 Mycophenolate mofetil (CellCept) 134 0.45508 Miconazole nitrate 135 0.45794 Erlotinib HCl 136 0.46496 Pimobendan (Vetmedin) 137 0.47266 Lopinavir (ABT-378) 138 0.49230 Atorvastatin calcium (Lipitor) 139 0.49668 Domperidone (Motilium) 140 0.50606 Pazopanib HCl 141 0.50713 Clotrimazole (Canesten) 142 0.50750 Anisindione 143 0.50955 Fenbendazole (Panacur) 144 0.51170 Idarubicin HCl 145 0.51598 Benserazide 146 0.51712 Monobenzone (Benoquin) 147 0.51961 Irinotecan HCl trihydrate (Campto) 148 0.52007 Fludarabine (Fludara) 149 0.52252 Catharanthine 150 0.53186 Guanabenz acetate 151 0.53343 Nicardipine HCl 152 0.53592 Propafenone (Rytmonorm) 153 0.53665 Oxethazaine 154 0.53820 Deferasirox (Exjade) 155 0.54810 Fluvastatin sodium (Lescol) 156 0.55240 Carbidopa 157 0.55688 Tamoxifen citrate (Nolvadex) 158 0.56146 Clofoctol 159 0.56674 Fludarabine phosphate (Fludara) 160 0.57685 Imipramine HCl 161 0.57921 Irinotecan 162 0.58316 Resveratrol 163 0.58708 Chloroxine 164 0.58754 Trifluridine (Viroptic) 165 0.58785 Tacrine HCl 166 0.59079 2-Methoxyestradiol 167 0.59196 Tolcapone 168 0.59902 Econazole nitrate (Spectazole) 169 0.60221 Oxaliplatin (Eloxatin) 170 0.60308 Eltrombopag (SB-497115-GR) 171 0.60500 Paclitaxel (Taxol) 172 0.60974 Tigecycline 173 0.61596 Ethinyl Estradiol 174 0.61637 Brucine 175 0.61657 Benidipine hydrochloride 176 0.61796 10-DAB (10-Deacetylbaccatin) 177 0.61920 Ketoconazole 178 0.61991 Tolterodine tartrate (Detrol LA) 179 0.62391 Dicyclomine HCl 180 0.62849 Cyproheptadine HCl (Periactin) 181 0.62937 Phenazopyridine HCl 182 0.63254 Bufexamac 183 0.63641 Ulipristal 184 0.64024 Isoetharine mesylate 185 0.64187 Ospemifene 186 0.65023 Sulconazole nitrate 187 0.65218 Docetaxel (Taxotere) 188 0.65646 Oxytetracycline (Terramycin) 189 0.65812 Fenticonazole nitrate 190 0.66034 Ritonavir 191 0.66217 Benzydamine hydrochloride 192 0.66512 Imidapril (Tanatril) HCl 193 0.66684 Idoxuridine 194 0.66777 Miconazole (Monistat) 195 0.67937 Manidipine (Manyper) 196 0.68048 Axitinib 197 0.68169 Floxuridine 198 0.68281 Chlorquinaldol 199 0.70334 Cisatracurium besylate (Nimbex) 200 0.71341 Ivabradine HCl (Procoralan) 201 0.72356 Mesoridazine besylate 202 0.73867 Atazanavir sulfate 203 0.74086 Loratadine 204 0.74200 Nitrofurazone (Nitrofural) 205 0.74507 Imatinib (Gleevec) 206 0.74830 Fidaxomicin 207 0.75269 Hydroxyzine 2HCl 208 0.75730 Arbidol HCl 209 0.75825 Quinine hydrochloride dihydrate 210 0.75982 Dibucaine HCL 211 0.76361 Gefitinib (Iressa) 212 0.76433 Nifedipine (Adalat) 213 0.76709 Meticrane 214 0.76796 Atracurium besylate 215 0.76961 Deoxyarbutin 216 0.77569 Thiabendazole 217 0.78225 Phentolamine mesilate 218 0.78355 Formoterol hemifumarate 219 0.78515 Azelnidipine 220 0.78897 Progesterone (Prometrium) 221 0.79385 Tioconazole 222 0.79787 BIBR-1048 (Dabigatran) 223 0.79839 Naftopidil (Flivas) 224 0.79949 Exemestane 225 0.80059 Ezetimibe (Zetia) 226 0.80144 Fenoprofen calcium hydrate 227 0.80162 Methazolamide 228 0.80200 Rimonabant (SR141716) 229 0.80972 Quinapril HCl (Accupril) 230 0.81385 Regorafenib (BAY 73-4506) 231 0.82073 Flunarizine 2HCl 232 0.82128 Clozapine (Clozaril) 233 0.82618 Cobicistat (GS-9350) 234 0.82656 Curcumin 235 0.83127 Ranitidine (Zantac) 236 0.83376 Tolperisone HCl 237 0.83788 Mianserin hydrochloride 238 0.83835 Diphenylpyraline HCl 239 0.84359 Alprostadil (Caverject) 240 0.84467 Pramiracetam 241 0.85274 Broxyquinoline 242 0.85420 Estradiol 243 0.85457 Clorgyline HCl 244 0.85579 Benztropine mesylate 245 0.86009 Scopolamine hydrobromide 246 0.86178 Levosimendan 247 0.86179 Epinephrine bitartrate (Adrenalinium) 248 0.86669 Serotonin HCl 249 0.87069 Budesonide 250 0.87180 Alverine Citrate 251 0.87755 Rimantadine (Flumadine) 252 0.88126 Terbinafine hydrochloride (Lamisil) 253 0.88370 Scopine 254 0.88499 Carmofur 255 0.88530 Conivaptan HCl (Vaprisol) 256 0.88551 Mifepristone (Mifeprex) 257 0.88611 Tetracycline HCl 258 0.88968 Ethoxzolamide 259 0.89124 Noscapine HCl 260 0.89630 Methacycline hydrochloride (Physiomycine) 261 0.89960 Oxybuprocaine HCl 262 0.90202 Tiotropium bromide hydrate 263 0.90270 Triclabendazole 264 0.90285 Temsirolimus (Torisel) 265 0.90419 Adrucil (Fluorouracil) 266 0.90446 Nilvadipine (ARC029) 267
Load more

Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000
    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
    [Show full text]
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Combined Effects of Celecoxib and Cepharanthine on Human Colorectal Cancer Cells in Vitro
    Journal of Applied Pharmaceutical Science Vol. 9(04), pp 117-125, April, 2019 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2019.90415 ISSN 2231-3354 Combined effects of celecoxib and cepharanthine on human colorectal cancer cells in vitro Parawee Lerdwanangkun1, Piyanuch Wonganan1, Robin James Storer2, Wacharee Limpanasithikul1* 1Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 2Office of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. ARTICLE INFO ABSTRACT Received on: 11/09/2018 Colorectal cancer is one of the most common cancers worldwide. We investigated the combined effects of celecoxib Accepted on: 22/01/2019 (CLX)–cepharanthine (CEP) on HT-29 human colorectal cancer cells. CLX at 5, 10, 20, or 40 µM in combination Available online: 18/04/2019 with CEP at 1.25, 2.5, or 5 µM displayed synergistic cytotoxic effects with a combination index <1. Combinations of 20 or 40 µM of CLX with 1.25 or 2.5 µM of CEP increased HT-29 cell accumulation at the G1 phase of the cell cycle. The combined treatments increased the levels of p21 mRNA and decreased the levels of cyclin-A2 mRNA. Their Key words: combined effect triggered significant apoptosis of HT-29 cells when compared with the effect of each drug alone. The Celecoxib, cepharanthine, apoptotic effects of the drugs were correlated with increases in the levels of mRNA for BAX and decreases in the colorectal cancer, apoptosis, levels of mRNA for Bcl-xL. The results from this study revealed that at concentrations that were sub-IC individually, cell cycle.
    [Show full text]
  • Arecoline Promotes Migration of A549 Lung Cancer Cells Through Activating the EGFR/Src/FAK Pathway
    toxins Article Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway Chih-Hsiang Chang 1,†, Mei-Chih Chen 2,3,†, Te-Huan Chiu 1 , Yu-Hsuan Li 1, Wan-Chen Yu 1, Wan-Ling Liao 1, Muhammet Oner 1, Chang-Tze Ricky Yu 4, Chun-Chi Wu 5, Tsung-Ying Yang 6, Chieh-Lin Jerry Teng 7, Kun-Yuan Chiu 8, Kun-Chien Chen 6, Hsin-Yi Wang 9, Chia-Herng Yue 10, Chih-Ho Lai 11 , Jer-Tsong Hsieh 12 and Ho Lin 1,13,14,* 1 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; [email protected] (C.-H.C.); [email protected] (T.-H.C.); [email protected] (Y.-H.L.); [email protected] (W.-C.Y.); [email protected] (W.-L.L.); [email protected] (M.O.) 2 Medical Center for Exosomes and Mitochondria Related Diseases, China Medical University Hospital, Taichung 40447, Taiwan; [email protected] 3 Department of Nursing, Asia University, Taichung 41345, Taiwan 4 Department of Applied Chemistry, National Chi Nan University, Nantou 54561, Taiwan; [email protected] 5 Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; [email protected] 6 Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] (T.-Y.Y.); [email protected] (K.-C.C.) 7 Division of Hematology/Medical Oncology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 8 Division of Urology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 9 Department of Nuclear Medicine, Taichung
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Dorset Medicines Advisory Group
    DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION SUMMARY The pan-Dorset cardiology working group continues to recommend the use of amlodipine (a third generation dihydropyridine calcium-channel blocker) as first choice calcium channel blocker on the pan-Dorset formulary for hypertension. Lercanidipine is second choice, lacidipine third choice and felodipine is fourth choice. This is due to preferable side effect profiles in terms of ankle oedema and relative costs of the preparations. Note: where angina is the primary indication or is a co-morbidity prescribers must check against the specific product characteristics (SPC) for an individual drug to confirm this is a licensed indication. N.B. Lacidipine and lercandipine are only licensed for use in hypertension. Chapter 02.06.02 CCBs section of the Formulary has undergone an evidence-based review. A comprehensive literature search was carried out on NHS Evidence, Medline, EMBASE, Cochrane Database, and UK Duets. This was for recent reviews or meta-analyses on calcium channel blockers from 2009 onwards (comparative efficacy and side effects) and randomised controlled trials (RCTs). REVIEW BACKGROUND Very little good quality evidence exists. No reviews, meta-analyses or RCTs were found covering all calcium channel blockers currently on the formulary. Another limitation was difficulty obtaining full text original papers for some of the references therefore having to use those from more obscure journals instead. Some discrepancies exist between classification of generations of dihydropyridine CCBs, depending upon the year of publication of the reference/authors’ interpretation. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) CCBs (diltiazem, verapamil), but the latter have greater inotropic effects.
    [Show full text]
  • NIH Public Access Author Manuscript Neuroscience
    NIH Public Access Author Manuscript Neuroscience. Author manuscript; available in PMC 2016 January 22. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neuroscience. 2015 January 22; 0: 775–797. doi:10.1016/j.neuroscience.2014.10.044. Early-life Exposure to the SSRI Paroxetine Exacerbates Depression-like Behavior in Anxiety/Depression-prone rats Matthew E. Glover1, Phyllis C. Pugh1, Nateka L. Jackson1, Joshua L. Cohen1, Andrew D. Fant2, Huda Akil3, and Sarah M. Clinton1,§ 1Department of Psychiatry and Behavioral Neurobiology, University of Alabama-Birmingham, USA 2Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA 3Molecular and Behavioral Neuroscience Institute, University of Michigan, USA Abstract Selective serotonin reuptake inhibitor (SSRI) antidepressants are the mainstay treatment for the 10–20% of pregnant and postpartum women who suffer major depression, but the effects of SSRIs on their children’s developing brain and later emotional health are poorly understood. SSRI use during pregnancy can elicit antidepressant withdrawal in newborns and increase toddlers’ anxiety and social avoidance. In rodents, perinatal SSRI exposure increases adult depression- and anxiety- like behavior, although certain individuals are more vulnerable to these effects than others. Our study establishes a rodent model of individual differences in susceptibility to perinatal SSRI exposure, utilizing selectively-bred Low Responder (bLR) and High Responder (bHR) rats that were previously bred for high versus low behavioral response to novelty. Pregnant bHR/bLR females were chronically treated with the SSRI paroxetine (10 mg/kg/day p.o.) to examine its effects on offspring’s emotional behavior and gene expression in the developing brain.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]